SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Boston harbor and cityscape skyline view
Job Trends
6 Companies Hiring Now in Boston
Looking for a biopharma job in Boston? Check out the BioSpace list of six companies hiring life sciences professionals like you.
October 2, 2025
 · 
1 min read
 · 
Angela Gabriel
IN PARTNERSHIP WITH PII
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
In this episode presented by PII, BioSpace’s head of insights discusses with guests Oliver Eden and Travis Webb how autoinjectors offer opportunities to improve delivery systems, patient compliance and clinical trial processes.
October 2, 2025
 · 
1 min read
 · 
BioSpace Insights
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
Both Halozyme and Elektrofi have partnered with several Big Pharma companies to provide drug delivery technologies.
October 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. Concept of choice, make a decision left or right, ability to think in a difficult situation, question of choosing between 2 directions. Illustration for web banner, social media banner. Vector illustration
Tariffs
Trump Delays Pharma Tariffs Yet Again
President Donald Trump last week announced that 100% pharma tariffs would come Oct. 1, but a White House official has clarified that that’s when the government will “begin preparing” the levies.
October 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Success Way and freedom. Business woman walking to the exit through an open door.
Cell therapy
Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality
Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move.
October 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of businessman balancing on a ball
Job Trends
High-Growth Areas, Development Roles May Offer More Job Security
With layoffs happening at biopharma companies of all sizes, some may wonder which jobs are safest. Talent acquisition experts spoke to BioSpace about the areas and roles they recommend to biotech and pharma professionals hoping to avoid staff cuts.
October 2, 2025
 · 
4 min read
 · 
Angela Gabriel
Difficult question concept. Big question mark or big problem to solve or finding solution, doubt or uncertainty, thinking to make decision, businessman holds up big question mark.
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
October 1, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease
As with recent rejections for Biogen and Scholar Rock, manufacturing issues stymied a regulatory bid from Fortress Biotech and Sentynl Therapeutics. Fortress said the FDA did not flag problems with the drug’s safety or efficacy.
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Government
US Government Shuts Down, FDA Closed for New Applications
Due to policies regarding industry user fees, the FDA will not be able to accept any new drug applications for the duration of the government shutdown, according to Leerink Partners.
October 1, 2025
 · 
4 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS